#1 Medical breakthrough of the Century – IPO This WednesdatTravis
Can you put the thinkolater to guess what this is all about?
Bonner & Partners teaser
A recent breakthrough in genetic engineering could finally cure – literally annihilate – 95% of the incurable diseases devastating humankind.
So far, there has been absolutely no way to for the average investor to get a share of the profits this medical breakthrough will undoubtedly deliver (billions for those involved at the start)…
That is, until now.
This week, on Wednesday February 3 at 9:30am, the tiny Boston firm at the forefront of this breakthrough is expected to finally go public.
It is the most well-funded, scientifically advanced and patented company in the entire space. Bill Gates, Google, and Fidelity (among others) are pouring hundreds of millions into its development.
In short, this is going to be huge. And you have an opportunity to pick up shares at the grand opening … before the media brings it to everyone’s attention.
I’ve prepared everything you need to know – the story, ticker symbol, buy-in price, and complete analysis – so you can make your decision before the Opening Bell this Wednesday morning.
Bottom line: You don’t want to miss this. You owe it to yourself to think it over.
Just click here now for the details. [ pro.bonnerandpartners.com/1601BITTEASER/EBITS202
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Four years ago, the protein called CRISPR-Cas9, an enzyme that bacteria use to attack viruses that infect them, was unknown to humans. Now it is ubiquitous in science labs as the most efficient way of cutting-and-pasting DNA yet invented. Wired Magazine, in a breathless cover story, just called it “The Genesis Engine,” instructing readers to “buckle up” because the easy DNA editing CRISPR enables will change the world. And now at least one CRISPR-focused company has the cash to back up the hype.
Editas Medicine, based in Cambridge, Mass., already had money. Founded in November 2013 with $43 million from Third Rock Ventures, Polaris Ventures and Flagship Ventures, it was the first big CRISPR effort out of the gate. The company says that money has not been spent. In May, Juno Therapeutics, which is developing cell therapies for cancer, inked a collaboration that gave Editas $25 million upfront and another $22 million in research support. Any products that result could deliver Editas another $250 million.
But those investments are dwarfed by today’s announcement, which will put $120 million into the tiny company’s bank account – enough, Editas says, to keep it running for a projected three years. The lead investor is a newly created firm called bng0, a select group of family offices led by Boris Nikolic, who was previously a science advisor to Bill Gates. Both Editas and Gates’ office confirm that the Microsoft MSFT -0.60% billionaire, who is the world’s richest man, is among the bng0 backers.
Editas Medicine (EDIT) plans to raise $100 million in an initial public offering on Wednesday, February 3rd. The company will issue 5,900,000 shares at a price of $16.00-$18.00 per share.
The company has a market-cap of $606.9 million.
Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Editas Medicine provided the following description of their company for its IPO: “We are a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. We believe that we have entered a new era of genomic medicine as the growth of genomic information in recent decades has significantly expanded the understanding of genetically defined diseases. A new technology known as CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) has the potential to achieve precise, directed changes in DNA. “.
Editas Medicine was founded in 2013 and has 55 employees. The company is located at 300 Third Street, First Floor, Cambridge, MA 02142, US and can be reached via phone at (617) 401-9000 or on the web at http://www.editasmedicine.com.
This is all readily available. I think this provides all info needed without our leader getting involved.
Thanks for the quick response … and actionable info.
Steve
EDIT a beauty of a sell off in a weak market down to IPO price. Going to be a lot of Crispr talk the rest of this week and into 2016.